NCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
10 trialsNCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06769126 2026-01-22
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT04699838 2026-01-02
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
NCT06680050 2025-12-18
AUSTRAL
Mario Negri Institute for Pharmacological Research
Phase 2 Recruiting
NCT05582538 2025-08-24
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Recruiting
NCT03740893 2025-08-11
PHOENIX
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT04298008 2024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Recruiting